Tradestie Institutional Equity Comparison Engine

ACON vs CDT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACON Overall Edge

ACON Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aclarion, Inc. Common Stock (ACON) driven by superior Momentum & Technical, Options & Structure while CDT counters with relative strength in Growth & Margin. Fundamentally, ACON trades at N/M Forward P/E with -10789.2% operating margin (+78.1% YoY revenue) versus CDT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ACON sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ACON N/M vs CDT N/M Fwd P/E
Growth & Margin Winner CDT
Op Margin -10789.2% vs 0.0% ยท YoY +78.1% vs +0.0%
Momentum & Technical Winner ACON
1Y -79.2% vs -86.8% ยท 52W Pos 0% vs 2%
Options & Structure Winner ACON
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
ACON NASDAQ
Aclarion, Inc. Common Stock
Services-Medical Laboratories
$1.22
-13.92% 1D
Market Cap $3.7M
1M Return -36.83%
1Y Return -79.18%
Forward P/E N/M
Unified AI Score
42.2 / 100 HOLD
Tech 30.0 Fund 55.0 Flow 50.0 Mom 59.0
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
1M Return +76.79%
1Y Return -86.78%
Forward P/E N/M
Unified AI Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ACON -79.18% CDT -86.78% Spread: +7.6 pp (ACON Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ACON TTM Op. Margin: -10789.2% CDT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACON vs CDT. Trailing 12-month operating profitability (ACON -10789.2% vs CDT 0.0%) and valuation multiples (ACON N/M vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ACON (3) vs CDT (3)
Institutional Metric ACON CDT Criterion Row Winner
Market Capitalization Scale $3.7M $507,528 Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +78.1% +0.0% Higher Growth ACON
Operating Margin (TTM) Profitability -10789.2% 0.0% Higher Margin CDT
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -74.1% -69.7% Higher ROE CDT
52-Week Range Position Momentum 0% ($1โ€“$9) 2% ($0โ€“$11) Stronger Trend CDT
Beta / 30D Volatility Risk Regime 1.36ฮฒ ยท 87% Vol -17.75ฮฒ ยท 10175% Vol Lower Realized Risk ACON
Unified Institutional Score Composite Signal 42.2 / 100 (HOLD) 31.6 / 100 (SELL) Higher Composite ACON

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ACON vs CDT Buy Guide
ACON UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ACON Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CDT BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CDT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ACON nor CDT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.